Mirtazapine treatment of Generalized Anxiety Disorder: a fixed dose, open label study

被引:41
作者
Gambi, F [1 ]
De Berardis, D [1 ]
Campanella, D [1 ]
Carano, A [1 ]
Sepede, G [1 ]
Salini, G [1 ]
Mezzano, D [1 ]
Cicconetti, A [1 ]
Penna, L [1 ]
Salerno, RM [1 ]
Ferro, FM [1 ]
机构
[1] Univ G DAnnunzio, Inst Psychiat, Dept Oncol & Neurosci, Palazzina SE BI Scuole Specializzaz, I-66013 Chieti, Italy
关键词
mirtazapine; generalized anxiety disorder; open label; pharmacotherapy;
D O I
10.1177/0269881105056527
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
We investigated the efficacy of mirtazapine in the treatment of generalized anxiety disorder (GAD). Forty-four adult outpatients with GAD were treated openly with a fixed dose of mirtazapine (30 mg) for 12 weeks. The primary outcome measure was the change from baseline in total score on the Hamilton Rating Scale for Anxiety (HAM-A). The Clinical Global Impression of Improvement (CGI-I) was rated at the endpoint. Patients with a reduction of 50% or more on the HAM-A total score and a CGI-I score of 1 or 2 at endpoint were considered responders to treatment; remission was defined as a HAM-A score <= 7. At 12 weeks, response was achieved by 79.5% of the patients (n = 35) and remission by 36.4% of patients (n = 16). This study supports the notion that mirtazapine is an efficacious and well tolerated treatment for GAD. Limitations of the present study must be considered and further placebo-controlled trials are needed.
引用
收藏
页码:483 / 487
页数:5
相关论文
共 25 条
[1]  
[Anonymous], 1994, AM PSYCHIATR ASSOC
[2]  
Ballenger JC, 1999, J CLIN PSYCHIAT, V60, P29
[3]   Efficacy and tolerability of mirtazapine and sertraline in Korean veterans with posttraumatic stress disorder: A randomized open label trial [J].
Chung, MY ;
Min, KH ;
Jun, YJ ;
Kim, SS ;
Kim, WC ;
Jun, EM .
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2004, 19 (07) :489-494
[4]   A pilot study of mirtazapine in post-traumatic stress disorder [J].
Connor, KM ;
Davidson, JRT ;
Weisler, RH ;
Ahearn, E .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1999, 14 (01) :29-31
[5]   Mirtazapine vs. placebo in posttraumatic stress disorder: A pilot trial [J].
Davidson, JRT ;
Weisler, RH ;
Butterfield, MI ;
Casat, CD ;
Connor, KM ;
Barnett, S ;
van Meter, S .
BIOLOGICAL PSYCHIATRY, 2003, 53 (02) :188-191
[6]   The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission [J].
deBoer, T .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1995, 10 :19-23
[7]  
Fava M, 2000, J CLIN PSYCHIAT, V61, P37
[8]   Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: An open-label trial [J].
Fava, M ;
Dunner, DL ;
Greist, JH ;
Preskorn, SH ;
Trivedi, MH ;
Zajecka, J ;
Cohen, M .
JOURNAL OF CLINICAL PSYCHIATRY, 2001, 62 (06) :413-420
[9]  
First M.B., 2007, STRUCTURED CLIN INTE
[10]   Mirtazapine in major depression with comorbid generalized anxiety disorder [J].
Goodnick, PJ ;
Puig, A ;
DeVane, CL ;
Freund, BV .
JOURNAL OF CLINICAL PSYCHIATRY, 1999, 60 (07) :446-448